Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1337, 2002-01, pp. : 8-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
CpG oligodeoxynucleotides: postexposure prophylaxis for prion diseases?
Inpharma, Vol. 1, Iss. 1348, 2002-01 ,pp. :
Access to resources
Recommend
Anti-CD137 immunotherapy for autoimmune diseases?
Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. :
Can IFN- be used in Guillain-Barré syndrome?
Inpharma, Vol. 1, Iss. 1252, 2000-01 ,pp. :
IFN- efficacy reduced by NAbs, but do they last?
Inpharma, Vol. 1, Iss. 1505, 2005-01 ,pp. :
IFN- cost effective for MS after all?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. :